The new government-funded clinical trial is will determine immune responses and reactogenicity from a third dose of one of seven different vaccines.
It will be the first study in the world to provide data on the impact of a third dose on patients’ immune responses., giving scientists a better idea of how effective a booster would be at protecting people.
The trial will look at seven different Covid-19 vaccines as potential boosters.
Inspectors at north Leeds care home find ‘unsupervised communal areas’ and patients visiting each other’s rooms uninvited
First confirmed cases of Monkeypox in Leeds
Refugee in Leeds 'considered returning to Ukraine' when faced with five-year wait to for NHS dentist
Caterpillar health app – how it works, what free rewards you get and why Leeds is part of the pilot
The life and crimes of Britain's most notorious prisoner Charles Bronson
Vaccines being trialled include Oxford/AstraZeneca, Pfizer/BioNTech, Moderna, Novavax, Valneva, Janssen and Curevac, as well as a control group.
One booster will be provided to each volunteer and could be a different brand to the one they were originally vaccinated with.
The boosters will be given at least 10 to 12 weeks after a second dose.
Initial results are expected in September and will help to inform the potential booster programme.
Dr Philip Wood, Chief Medical Officer at Leeds Teaching Hospitals NHS Trust said: “Leeds Teaching Hospitals NHS Trust is delighted to be involved in the Cov-Boost study.
"This builds on successful research activities that have taken place at the Trust and across Leeds during the pandemic, including the Novavax vaccine trial and the Public Health England-led SIREN study.
“This vital research will help us to understand the potential benefits to people across the UK and internationally of booster vaccinations in becoming fully protected against COVID-19.
"We urge people who are aged over 70 years old from across Leeds to take part in the Cov-Boost stud and be part of this research.”
Participants will be adults aged 30 years or older and will include those immunised early on in the vaccination programme - for example, adults aged 75 and over or health and care workers.
The study is taking place at 16 NIHR-supported sites across the UK, and will include a total of 2,886 patients.
People in Leeds, especially those aged over 70 years old are asked to sign up to the NHS vaccine registry at nhs.uk/researchcontact.